Cue Biopharma shares surge on positive mid-stage study results for CUE-221
Cue Biopharma shares soared 28.9% in premarket trading after the company announced positive results from its mid-stage study for CUE-221 in hives treatment. The company stated that the phase 2 primary and key secondary endpoints were met. Earlier in the month, Cue Biopharma reported that its Q2 revenue more than doubled.
74 in premarket trading after the company reported positive results from a mid-stage study of CUE-221 for hives treatment. The company said the phase 2 primary and key secondary endpoints were met. Earlier this month, CUE's Q2 revenue more than doubled. Up to the previous day's close, the shares were up more than 300% year to date.